Locally Advanced Rectal Cancer – Epidemiology Insights and Forecast Report – 2020 To 2040

Locally Advanced Rectal Cancer Epidemiology Insights

Thelansis’s “Locally Advanced Rectal Cancer Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Locally Advanced Rectal Cancer Overview

Locally advanced rectal cancer refers to tumors that have deeply penetrated the rectal wall (beyond the muscularis propria) and may include regional lymph node involvement or invasion of nearby pelvic structures, classified as Stage II or Stage III disease without distant spread. This condition presents a significant therapeutic challenge due to the tumor’s close anatomical relationship to vital pelvic organs and the resulting high risk of locoregional recurrence. Symptoms can include rectal bleeding, changes in bowel habits, pelvic pain, or tenesmus, requiring comprehensive staging via colonoscopy, biopsy, and high-resolution pelvic MRI. Multidisciplinary management typically begins with neoadjuvant chemoradiotherapy, which is designed to shrink and downstage the tumor, maximizing the chance of a curative Total Mesorectal Excision (TME)—the gold-standard surgery to remove the rectum and its surrounding lymphatic tissue.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Locally Advanced Rectal Cancer – Epidemiology Insights and Forecast Report – 2020 To 2040